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Background: Clinically important Gram-positive and -negative isolates were collected from patients in France between
2004 and 2012 as a part of the Tigecycline Evaluation and Surveillance Trial.
Methods: MICs were determined using methodology described by the Clinical and Laboratory Standards Institute.
Results: In total, 17,135 isolates were contributed by 29 medical centres; respiratory (25.1%) and cardiovascular (20.3%)
sources predominated. High susceptibility was observed among Enterococcus spp. and Staphylococcus aureus (including
methicillin-resistant S. aureus [MRSA]) to linezolid (100%), tigecycline (≥99.8%) and vancomycin (≥94.6%). The
percentage of MRSA decreased from 34.3% in 2004 to 20.0% in 2009 before increasing to 34.7% in 2012. Vancomycin,
linezolid, levofloxacin and carbapenems were highly active (≥99.6%) against Streptococcus pneumoniae; 3.2% were PRSP.
Escherichia coli showed peak susceptibility to the carbapenems (≥99.9%), tigecycline (99.3%) and amikacin (97.9%);
significant (p < 0.01) decreases in susceptibility were observed for ampicillin, cefepime and ceftriaxone between
2004 and 2012. ESBL production among E. coli increased from 3.0% (2004) to 14.9% (2012). High susceptibility
was noted among Haemophilus influenzae to levofloxacin (100%), amoxicillin-clavulanate (99.2%), carbapenems
(≥98.7%) and ceftriaxone (98.5%); β-lactamase production fluctuated with no notable trend between 18.1% (2007)
and 27.7% (2011). Klebsiella spp. were highly susceptible to carbapenems (≥99.6%) and amikacin (≥96.4%); significant
(p < 0.01) decreases in amoxicillin-clavulanate, cefepime, ceftriaxone, levofloxacin, piperacillin-tazobactam and
tigecycline susceptibility were observed among K. pneumoniae between 2004 and 2012. Only imipenem was highly
active (96.5% susceptible) against Acinetobacter baumannii. Imipenem and amikacin (87.7% and 87.1% susceptible) were
the most active agents against P. aeruginosa; 10.2% of isolates were categorized as multidrug resistant.
Conclusions: Carbapenems, linezolid, tigecycline and vancomycin conserved good in vitro activity against most
pathogens (according to their spectrum of activity) in France between 2004 and 2012.
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France is home to one of the highest rates of antibiotic
consumption and antimicrobial resistance in Europe [1],
and has experienced rapidly changing trends of antimicro-
bial resistance in recent years. The European Antimicro-
bial Resistance Surveillance Network (EARS-Net) has
reported significantly increasing levels of resistance in
France [2], where 10.8% of Escherichia coli and 23.7% of
Klebsiella pneumoniae isolates were reported to be inter-
mediate or resistant to third-generation cephalosporins in
2012 (as compared with 1.9% in 2002 and 5.1% in 2005,
respectively) [3]. Several programmes have been initiated
to combat these increasing levels of resistance, including
measures to control transmission of resistant pathogens,
to promote the use of alcohol-based hand-rub solution
in hospitals, to control/prevent the spread of emerging
multidrug-resistant (MDR) organisms (i.e., vancomycin-
resistant enterococci [VRE], carbapenemase-producing
Enterobacteriaceae) and to decrease antibiotic consump-
tion [4]. These efforts have paid at least some dividends:
declining levels of antimicrobial resistance have been re-
ported in recent years among French isolates of Strepto-
coccus pneumoniae to penicillin (from 36.2% in 2005 to
23.4% in 2012) and Staphylococcus aureus to methicillin
(from 33.4% in 2001 to 19.1% in 2012) [3].
Tigecycline is a broad-spectrum antimicrobial agent
which has been indicated for use in the treatment of
complicated skin and skin structure infections (cSSTIs)
and complicated intra-abdominal infections (cIAIS) (and
in the USA, community-acquired bacterial pneumonia)
[5]. The Tigecycline Evaluation and Surveillance Trial
(T.E.S.T.) is a global surveillance study which commenced
in 2004, with the intention of monitoring the activity of
the broad-spectrum glycylcycline tigecycline and a panel
of comparator agents against an array of clinically import-
ant Gram-positive and Gram-negative organisms. In
this study, we examine the activity of tigecycline and
comparators against clinically important Gram-positive
and Gram-negative pathogens collected from community
and nosocomial patients in France between 2004 and
2012. This manuscript serves as an update to Rodloff et al.
[6], who described a collection of isolates from France,
Germany, Italy, Spain and the U.K. collected as a part
of T.E.S.T. between 2004 and 2006, as well as Nørskov-
Lauritsen et al. [7], who presented data on European iso-
lates (including France) collected between 2004 and 2007.
Methods
Between 2004 and 2012 there were 29 centres in France.
The majority of these centres were university hospitals.
No centres contributed in all 9 study years. Three centres
contributed in 8 years, two in 7 years, four in 6 years, six
in 5 years, three in 4 years, three in 3 years, five in 2 years,
and three in a single year.Bacterial isolates
Each centre was required to submit a minimum of 65
Gram-positive isolates and 135 Gram-negative isolates, in-
cluding at least 25 S. aureus, 15 Enterococcus spp., 15 S.
pneumoniae, 10 Streptococcus agalactiae, 25 Klebsiella
spp., 25 E. coli, 25 Enterobacter spp., 20 Pseudomonas
aeruginosa, 15 Acinetobacter spp., 15H. influenzae and
10 Serratia spp. isolates. Each submitted isolate had to
be considered by the contributing centre to be of clinical
significance as the probable causative agent of a hospital-
or community-acquired infection. All body sites were con-
sidered acceptable isolate sources for this study, including
body fluid, central nervous system, cardiovascular system,
gastro-intestinal, genito-urinary (no more than 25% of iso-
lates from any centre), head, ears, eyes, nose and throat,
integument, lymph, muscular, reproductive, respiratory,
skeletal or medical instruments (i.e. catheters, drains,
forceps, probes). No banked or stored isolates or dupli-
cate isolates from a single patient were accepted into the
T.E.S.T. study. Isolate inclusion was independent of pa-
tient age, sex, antimicrobial use and/or medical history.
All isolates were sent to a single reference laboratory,
International Health Management Associates (IHMA,
Schaumburg, IL), which was responsible for organism col-
lection and transport and organism identification confirm-
ation and development. IHMA also undertook creation
and management of a centralized isolate database. Quality
control (QC) checks were carried out by IHMA on ap-
proximately 10% of isolates annually.
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were de-
termined locally using broth microdilution method-
ology as described by the Clinical and Laboratory
Standards Institute (CLSI) [8] using either MicroScan®
panels (Dade Behring Inc., CA, USA) or Sensititre®
plates (TREK Diagnostic Systems, West Sussex, England).
The test panel for the T.E.S.T. study included amikacin
(AMK), amoxicillin-clavulanate (AMC), ampicillin (AMP),
cefepime (CFP), ceftazidime (CTZ), ceftriaxone (CRO),
imipenem (IMP), levofloxacin (LEV), linezolid (LZD),
meropenem (MER), minocycline (MIN), penicillin (PEN),
piperacillin-tazobactam (PTZ), tigecycline (TIG) and
vancomycin (VAN). Imipenem was replaced in 2006 by
meropenem due to stability issues associated with imi-
penem and MicroScan® panels were replaced by Sensititre®
the same year. After 2006, the test panel for S. pneumo-
niae also included azithromycin (AZI), clarithromycin
(CLA), erythromycin (ERY) and clindamycin (CLI).
Clinical categorization was done using the 2013 breakpoints
established by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [9]. Data are included
in the tables only when interpretive breakpoints are
available.
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among E. coli and Klebsiella spp. was identified by
IHMA using cefotaxime (30 μg), cefotaxime-clavulanic
acid (30/10 μg), ceftazidime (30 μg), and ceftazidime-
clavulanic acid (30/10 μg) discs [10]. A positive ESBL
result was designated by an increase of ≥5 mm in the
inhibition zone on the combination disc compared with
the corresponding cephalosporin disc. Discs were manu-
factured by Oxoid, Inc. (Ogdensburg, NY, USA); Mueller-
Hinton agar was produced by Remel, Inc. (Lenexa, KS,
USA). H. influenzae isolates were tested for β-lactamase
production using locally preferred methodologies. Multi-
drug resistance was defined as resistance to three or more
classes of antimicrobial agent, and only included antimi-
crobials with available breakpoints. For A. baumannii
antimicrobials classes (and agents) included in the analysis
were aminoglycosides [AMK], carbapenems [IMP or
MER], and fluoroquinolones [LEV]. For P. aeruginosa anti-
microbial classes (and agents) included in the analysis were
aminoglycosides [AMK], β-lactams [CFP, CTZ, PTZ], car-
bapenems [IMP or MER], and fluoroquinolones [LEV].
Daily QC testing was performed using QC strains En-
terococcus faecalis ATCC 29212, S. aureus ATCC 29213,
S. pneumoniae ATCC 49619, E. coli ATCC 25922, P. aer-
uginosa ATCC 27853 and H. influenzae ATCC 49247
and ATCC 49766, as appropriate. QC strains used for
ESBL testing were K. pneumoniae ATCC 700603 (ESBL-
positive) and E. coli ATCC 25922 (ESBL-negative), while
P. aeruginosa (ATCC 27853) was used for the QC of cef-
tazidime and cefotaxime discs. Information on T.E.S.T.
study protocols can be found online [5].
Longitudinal data were examined for statistically signifi-
cant changes in susceptibility between 2004 and 2012
using the Cochran Armitage Trend Test. A positive
change reflected a statistically significant decrease in sus-
ceptibility, while a negative change indicated that suscepti-
bility had increased significantly. A p < 0.01 was used in
this analysis as a cut-off value for statistical significance
(a significance value of p < 0.05 was not used here as com-
puting a high volume of statistical tests can lead to signifi-
cant results purely by chance; setting a lower significance
value greatly reduces the chance of this happening).
Results
Isolates were collected from 29 centres in France between
2004 and 2012 (eight in 2004, six in 2005, 12 in 2006, 16
in 2007, 21 in 2008, 20 in 2009, 15 in 2010, five in 2011
and 23 in 2012) as a part of the T.E.S.T surveillance study.
Gram-positive pathogens
Enterococcus spp.
Between 2004 and 2012, 969 isolates of E. faecalis and 332
Enterococcus faecium isolates were examined as a part of
the T.E.S.T. study (Table 1). Both species were highlysusceptible to linezolid (both 100%), tigecycline (99.8%
and 100%, respectively) and vancomycin (99.3% and
94.6%, respectively). E. faecalis were also highly suscep-
tible to amoxicillin-clavulanate, ampicillin and imipenem
(>96%), while E. faecium were not (≤25% susceptible). De-
creases in E. faecalis susceptibility between 2004 and 2012
to amoxicillin-clavulanate (100% to 96.7%) and ampicillin
(100% to 95.4%) were small but statistically significant
(p < 0.01 and p < 0.001, respectively). Of note, vancomycin
resistance was observed in 0.7% of E. faecalis isolates
(increasing from 0.0% in 2004 to 1.3% in 2012) and 5.4%
of E. faecium isolates (increasing from 0.0% in 2004 to
4.3% in 2012) between 2004 and 2012 in France. Linezolid
and tigecycline activity were unaffected by vancomycin re-
sistance (Table 2).
S. aureus
All (N = 2229) S. aureus isolates were susceptible to linez-
olid, tigecycline and vancomycin, including MRSA iso-
lates, while 93.7% were susceptible to minocycline
(Table 1). The percentage of S. aureus identified as MRSA
in France decreased from 34.3% in 2004 to 20.0% in 2009,
but increased to 34.7% in 2012; the average MRSA rate
over the total course of the study was 28.3% (Table 3).
There was a statistically significant (p < 0.001) increase in
minocycline susceptibility among MRSA over the study
duration (Table 2). Methicillin resistance had no impact
on the activity of linezolid, minocycline, tigecycline or
vancomycin.
S. agalactiae
S. agalactiae (N = 859) were highly susceptible to most
agents on the TEST panel where breakpoints exist, the
notable exception being minocycline (against which only
15.4% of isolates were susceptible) (Table 1).
S. pneumoniae
S. pneumoniae (N = 990) were highly susceptible to
vancomycin (100%), linezolid (99.9%) and levofloxacin
(99.6%). Imipenem and meropenem were also highly ac-
tive (100% and 99.9% susceptibility, respectively), although
only tested against a subset of isolates (n = 120 and n =
870) (Table 1). A MIC90 of 0.06 mg/L was reported for
tigecycline (no tigecycline breakpoints are available).
Statistically significant changes in susceptibility were
observed between 2004 and 2012 for clindamycin (in-
creasing from 52.3% to 67.4%; p < 0.01) and minocycline
(decreasing from 55.8 to 50.3%; p < 0.01) (Additional
file 1: Table S1). No penicillin-resistant S. pneumoniae
(PRSP) were collected in 2004 or 2011 (Table 3). The
highest rate of penicillin resistance was reported in
2006 (4.6%). The PRSP rate over the 2004–2012 period
in France was 3.2% (Table 3). A statistically significant
(p < 0.01) increase in clindamycin susceptibility was
Table 1 Minimum inhibitory concentrations (MIC50, MIC90,
MIC range [mg/L]) and antimicrobial susceptibility (%S)
of clinically important Gram-positive and Gram-negative
isolates
Pathogen N MIC50 MIC90 MIC Range %S
Gram-positive
E. faecalis
AMC 969 0.5 1 ≤0.03 - ≥16 99.1
AMP 969 1 2 ≤0.06 - ≥32 98.8
IMP 137 1 4 ≤0.12 - 16 96.4
LZD 969 2 2 ≤0.5 - 4 100
TIG 969 0.12 0.25 ≤0.008 - 0.5 99.8
VAN 969 1 2 0.25 - ≥64 99.3
E. faecium
AMC 332 ≥16 ≥16 0.06 - ≥16 25.0
AMP 332 ≥32 ≥32 ≤0.06 - ≥32 22.3
IMP 29 ≥32 ≥32 2 - ≥32 20.7
LZD 332 2 2 ≤0.5 - 2 100
TIG 332 0.06 0.25 0.03 - 0.25 100
VAN 332 1 2 0.25 - ≥64 94.6
S. aureus
LEV 2229 0.25 16 ≤0.06 - ≥64 71.7
LZD 2229 2 2 ≤0.5 - 4 100
MIN 2229 ≤0.25 0.5 ≤0.25 - ≥16 93.7
PEN 2229 8 ≥16 ≤0.06 - ≥16 14.4
TIG 2229 0.12 0.25 ≤0.008 - 0.5 100
VAN 2229 1 1 ≤0.12 - 2 100
S. agalactiae
LEV 859 0.5 1 ≤0.06 - 32 97.1
LZD 859 1 1 ≤0.5 - 2 100
MIN 859 8 ≥16 ≤0.25 - ≥16 15.4
PEN 859 ≤0.06 0.12 ≤0.06 - 0.12 100
TIG 859 0.06 0.12 0.015 - 0.25 100
VAN 859 0.5 0.5 ≤0.12 - 1 100
S. pneumoniae
AMP 990 ≤0.06 2 ≤0.06 - ≥32 68.2
AZI 872 0.12 ≥128 ≤0.03 - ≥128 56.5
CRO 990 0.06 1 ≤0.03 - 16 79.1
CLA 872 0.06 ≥128 ≤0.015 - ≥128 57.0
CLI 872 0.06 ≥128 ≤0.015 - ≥128 65.0
ERY 872 0.12 ≥128 ≤0.015 - ≥128 56.4
IMP 120 ≤0.12 0.25 ≤0.12 - 0.5 100
LEV 990 1 1 ≤0.06 - ≥64 99.6
LZD 990 1 1 ≤0.5 - 4 99.9
MER 870 ≤0.12 0.5 ≤0.12 - ≥32 99.9
MIN 990 1 8 ≤0.25 - ≥16 47.6
Table 1 Minimum inhibitory concentrations (MIC50, MIC90,
MIC range [mg/L]) and antimicrobial susceptibility (%S)
of clinically important Gram-positive and Gram-negative
isolates (Continued)
PEN 990 ≤0.06 2 ≤0.06 - ≥16 51.3
VAN 990 0.25 0.5 ≤0.12 - 1 100
Gram-negative
E. aerogenes
AMK 561 2 8 ≤0.5 - 64 95.9
CFP 561 ≤0.5 2 ≤0.5 - ≥64 87.0
CRO 561 0.5 32 ≤0.06 - ≥128 56.7
IMP 81 0.5 1 ≤0.06 - 4 97.5
LEV 561 0.06 ≥16 ≤0.008 - ≥16 76.5
MER 480 ≤0.06 0.12 ≤0.06 - 8 98.3
PTZ 561 8 64 0.25 - ≥256 59.5
TIG 561 0.5 2 0.12 - 16 87.0
E. cloacae
AMK 1665 1 4 ≤0.5 - ≥128 96.7
CFP 1665 ≤0.5 8 ≤0.5 - ≥64 66.5
CRO 1665 1 ≥128 ≤0.06 - ≥128 50.7
IMP 226 0.5 1 ≤0.06 - 8 99.1
LEV 1665 0.06 ≥16 ≤0.008 - ≥16 73.1
MER 1439 ≤0.06 0.25 ≤0.06 - ≥32 99.4
PTZ 1665 4 ≥256 ≤0.06 - ≥256 59.3
TGC 1665 0.5 2 0.06 - 16 85.0
E. coli
AMK 2284 2 4 ≤0.5 - ≥128 97.9
AMC 2284 8 32 0.25 - ≥64 70.8
AMP 2284 ≥64 ≥64 ≤0.5 - ≥64 38.4
CFP 2284 ≤0.5 8 ≤0.5 - ≥64 84.3
CRO 2284 ≤0.06 64 ≤0.06 - ≥128 84.0
IMP 324 0.25 0.5 ≤0.06 - 2 100
LEV 2284 0.03 ≥16 ≤0.008 - ≥16 79.9
MER 1960 ≤0.06 ≤0.06 ≤0.06 - 4 99.9
PTZ 2284 2 16 ≤0.06 - ≥256 89.0
TGC 2284 0.25 0.5 ≤0.008 - 2 99.3
H. influenzae
AMC 1191 0.5 1 ≤0.12 - 16 99.2
AMP 1191 ≤0.5 32 ≤0.5 - ≥64 75.6
CRO 1191 ≤0.06 ≤0.06 ≤0.06 - 4 98.5
IMP 156 0.25 0.5 ≤0.06 - 4 98.7
LEV 1191 0.015 0.015 ≤0.008 - 1 100
MER 1035 ≤0.06 0.12 ≤0.06 - 0.5 100
MIN 1191 ≤0.5 1 ≤0.5 - 16 90.8
K. oxytoca
AMK 695 1 4 ≤0.5 - ≥128 98.7
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Table 1 Minimum inhibitory concentrations (MIC50, MIC90,
MIC range [mg/L]) and antimicrobial susceptibility (%S)
of clinically important Gram-positive and Gram-negative
isolates (Continued)
AMC 695 2 32 0.25 - ≥64 79.7
CFP 695 ≤0.5 2 ≤0.5 - ≥64 89.2
CRO 695 ≤0.06 8 ≤0.06 - ≥128 83.3
IMP 102 0.25 0.5 ≤0.06 - 1 100
LEV 695 0.06 1 ≤0.008 - ≥16 90.5
MER 593 ≤0.06 ≤0.06 ≤0.06 - ≥32 99.7
PTZ 695 2 ≥256 ≤0.06 - ≥256 83.3
TGC 695 0.25 1 0.015 - 8 95.4
K. pneumoniae
AMK 1524 1 4 ≤0.5 - ≥128 96.4
AMC 1524 4 32 0.5 - ≥64 72.6
CFP 1524 ≤0.5 32 ≤0.5 - ≥64 79.4
CRO 1524 ≤0.06 ≥128 ≤0.06 - ≥128 77.2
IMP 211 0.25 0.5 ≤0.06 - 2 100
LEV 1524 0.06 8 ≤0.008 - ≥16 82.2
MER 1313 ≤0.06 ≤0.06 ≤0.06 - ≥32 99.6
PTZ 1524 2 64 0.12 - ≥256 81.3
TGC 1524 0.5 2 0.06 - 16 87.6
S. marcescens
AMK 895 2 4 ≤0.5 - ≥128 97.1
CFP 895 ≤0.5 1 ≤0.5 - ≥64 94.4
CRO 895 0.25 8 ≤0.06 - ≥128 80.4
IMP 118 0.5 1 ≤0.06 - 4 96.6
LEV 895 0.12 2 0.015 - ≥16 87.2
MER 777 ≤0.06 0.12 ≤0.06 - ≥32 98.7
PTZ 895 2 16 ≤0.06 - ≥256 88.7
TGC 895 1 2 0.015 - 8 80.1
A. baumannii
AMK 1161 4 64 ≤0.5 - ≥128 75.6
IMP 170 0.5 2 ≤0.06 - ≥32 96.5
LEV 1161 0.25 8 ≤0.008 - ≥16 56.8
MER 991 0.5 8 ≤0.06 - ≥32 83.7
P. aeruginosa
AMK 1780 4 16 ≤0.5 - ≥128 87.1
CFP 1780 4 32 ≤0.5 - ≥64 77.5
CTZ 1780 ≤8 32 ≤8 - ≥64 75.6
IMP 260 1 8 0.12 - ≥32 87.7
LEV 1780 1 ≥16 ≤0.008 - ≥16 58.3
MER 1520 0.5 8 ≤0.06 - ≥32 75.4
PTZ 1780 8 ≥256 0.12 - ≥256 72.5
AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; CFP, cefepime;
CTZ, ceftazidime; CRO, ceftriaxone; IMP, imipenem; LEV, levofloxacin; LZD, linezolid;
MER, meropenem; MIN, minocycline; PEN, penicillin; PTZ, piperacillin-tazobactam;
TIG, tigecycline; VAN, vancomycin.
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levofloxacin, linezolid, meropenem, and vancomycin were
largely unaffected by penicillin resistance (Table 2). The




Meropenem, imipenem and amikacin were the most ac-
tive agents against Enterobacter spp., with 98.3% (n = 480),
97.5% (n = 81) and 95.9% of E. aerogenes (N = 561) and
99.4% (n = 1439), 99.1% (n = 226) and 96.7% of E. cloacae
(N = 1665) isolates susceptible, respectively (Table 1). E.
aerogenes and E. cloacae were 87.0% and 85.0% susceptible
to tigecycline, respectively. No statistically significant
changes in susceptibility over time were reported for
Enterobacter spp..
E. coli
E. coli (N = 2284) were highly susceptible to imipenem
(100%; n = 324), meropenem (99.9%; n = 1960), tigecycline
(99.3%) and amikacin (97.9%). Statistically significant de-
creases in susceptibility were observed to ampicillin (p <
0.001; 55.4% to 33.2%), cefepime (p < 0.0001; 97.0% to
81.7%) and ceftriaxone (p < 0.0001; 96.0% to 81.1%) be-
tween 2004 and 2012 (Additional file 1: Table S1). The
percentage of ESBL-positive E. coli isolates increased from
3.0% in 2004 to 14.9% in 2012, reaching a maximum of
17.5% in 2009 (Table 3). Statistically significant increases
in susceptibility were observed among ESBL-positive E.
coli to amikacin (p < 0.001), amoxicillin-clavulanate (p <
0.001), levofloxacin (p < 0.01) and piperacillin-tazobactam
(p < 0.01) (Table 2). Carbapenem and tigecycline activity
were not impacted by ESBL production (Table 2).
H. influenzae
All isolates of H. influenzae (N = 1191) were susceptible to
levofloxacin and meropenem (n = 1035); susceptibility was
also high to amoxicillin-clavulanate (99.2%), imipenem
(98.7%; n = 156) and ceftriaxone (98.5%). The MIC90 of
tigecycline was 0.25 mg/L. The percentage of β-lactamase
positive isolates did not change notably between 2004 and
2012 (Table 3). As expected, the in vitro activity of ampi-
cillin was dramatically reduced against β-lactamase-
positive H. influenzae (Table 2).
Klebsiella spp.
Both K. oxytoca (N = 695) and K. pneumoniae (N = 1524)
were fully susceptible to imipenem (n = 102 and 211, re-
spectively). High levels of susceptibility were also reported
for meropenem (99.7% [n = 593] and 99.6% [n = 1313],
respectively) and amikacin (98.7% and 96.4%, respectively)
(Table 1). Statistically significant decreases in susceptibility
were observed among K. pneumoniae to amoxicillin-
Table 2 MIC90 (mg/L), antimicrobial susceptibility (%S)
and statistically significant changes in susceptibility
among resistant pathogen phenotypes




(n = 18 [0/18])
AMC ≥16 16.7 N.S.
AMP ≥32 16.7 N.S.
LZD 2 100 -
TIG 0.25 100 -
VAN ≥64 0.0 -
S. aureus, MRSA
(n = 631 [77/554])
LEV 32 13.2 N.S.
LZD 2 100 -
MIN 0.5 93.5 p < 0.001 (−)
PEN ≥16 0.0 -
TIG 0.25 100 -
VAN 1 100 -
S. pneumoniae, PRSP
(n = 32; 31b)
AMP 8 0.0 -
AZI ≥128 19.4 N.S.
CRO 2 6.3 N.S.
CLA ≥128 19.4 N.S.
CLI ≥128 32.3 p < 0.01 (−)
ERY ≥128 19.4 N.S.
LEV 2 96.9 N.S.
LZD 1 100 -
MER 1 96.9 N.S.
MIN ≥16 18.8 N.S.
PEN 4 0.0 -
VAN 0.5 100 -
Gram-negative
E. coli, ESBL
(n = 275 [17/258])
AMK 8 90.5 p < 0.001 (−)
AMC 32 36.7 p < 0.001 (−)
AMP ≥64 0.0 -
CFP ≥64 4.7 N.S.
CRO ≥128 0.0 -
IMP 0.5 100 -
LEV ≥16 37.8 p < 0.01 (−)
MER ≤0.06 100 -
PTZ 64 72.4 p < 0.01 (−)
TIG 0.5 98.9 N.S.
H. influenzae, BL-Pos
(n = 269 [32/237])
AMC 2 98.1 N.S.
AMP ≥64 0.4 N.S.
CRO ≤0.06 97.4 N.S.
IMP 1 100 -
Table 2 MIC90 (mg/L), antimicrobial susceptibility (%S)
and statistically significant changes in susceptibility
among resistant pathogen phenotypes (Continued)
LEV 0.015 100 -
MER 0.12 100 -
MIN 1 92.6 N.S.
K. pneumoniae, ESBL
(n = 274 [19/255])
AMK 16 85.0 N.S.
AMC 32 16.1 N.S.
CFP ≥64 7.3 N.S.
CRO ≥128 1.8 N.S.
IMP 0.5 100 N.S.
LEV ≥16 29.6 N.S.
MER 0.12 98.4 -
PTZ ≥256 39.4 N.S.
TIG 2 78.1 N.S.
aA negative (−) change in significance indicates an increase in susceptibility;
N.S., not significant. A cut-off of p < 0.1 was used for statistical significance
testing.
Values given in square parentheses refer to the number of isolates tested against
imipenem and meropenem, respectively (and, where different, ampicillin [b]).
Only seven vancomycin-resistant E. faecalis were collected during this study;
data not presented.
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0.0001; 95.5% to 69.9%), ceftriaxone (p < 0.0001; 90.9%
to 69.9%), levofloxacin (p < 0.0001; 93.9% to 77.4%),
piperacillin-tazobactam (p < 0.0001; 95.5% to 82.4%)
and tigecycline (p < 0.01; 93.9% to 84.9%) over the
2004–2012 interval (Additional file 1: Table S1). ESBL
production among K. pneumoniae isolates increased
from 7.6% in 2004 to 23.0% in 2012 (Table 3). Carba-
penem activity was not impacted by ESBL production,
while amikacin and tigecycline activity decreased by ap-
proximately 10% (Table 2). No statistically significant
changes in susceptibility were reported for K. oxytoca.S. marcescens
The most active antimicrobial agents in this study
against S. marcescens (N = 895) were meropenem (98.7%
susceptible; n = 777), amikacin (97.1% susceptible), imi-
penem (96.6% susceptible; n = 118) and cefepime (94.4%
susceptible). No statistically significant changes in sus-
ceptibility over time were reported.A. baumannii
The most active agent against A. baumannii (N = 1161)
was imipenem (96.5% susceptible; n = 170), although
data are only available up to 2007 (Table 1). No break-
point is available for tigecycline, for which a MIC90 of
1 mg/L was recorded. Multidrug resistance was reported
among 4.7% of A. baumannii isolates between 2004 and
2012, reaching a maximum of 6.7% in 2010 (Table 3).
Table 3 Percentages of resistant phenotypes among Gram-positive and Gram—negative isolates by year, 2004–2012
Pathogen 2004 2005 2006 2007 2008 2009 2010 2011 2012 2004-12
N n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Gram-positive
E. faecalis, VRE 969 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 0 (0.0) 2 (1.1) 1 (0.7) 1 (3.8) 2 (1.3) 7 (0.7)
E. faecium, VRE 332 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.9) 8 (10.8) 2 (3.3) 3 (5.5) 1 (6.7) 2 (4.3) 18 (5.4)
S. aureus, MRSA 2229 34 (34.3) 20 (31.7) 40 (30.5) 88 (29.6) 135 (28.2) 77 (20.0) 75 (26.1) 15 (23.4) 147 (34.7) 631 (28.3)
S. pneumoniae, PRSP 990 0 (0.0) 1 (3.4) 3 (4.6) 3 (2.0) 9 (4.5) 7 (4.0) 6 (4.1) 0 (0.0) 3 (2.0) 32 (3.2)
Gram-negative
A. baumannii, MDR 1161 0 (0.0) 0 (0.0) 2 (2.0) 7 (4.9) 12 (5.2) 12 (5.2) 13 (6.7) 1 (3.0) 7 (4.7) 54 (4.7)
E. coli, ESBL 2284 3 (3.0) 2 (3.7) 8 (4.6) 18 (6.5) 58 (11.8) 75 (17.5) 46 (13.9) 13 (16.9) 52 (14.9) 275 (12.0)
H. influenzae, BL-Pos 1191 13 (23.2) 6 (23.1) 17 (27.4) 30 (18.1) 53 (21.1) 56 (25.0) 36 (23.7) 13 (27.7) 45 (21.7) 269 (22.6)
K. pneumoniae, ESBL 1524 5 (7.6) 5 (9.3) 9 (10.3) 20 (12.3) 64 (18.6) 47 (16.4) 58 (24.9) 11 (22.0) 55 (23.0) 274 (18.0)
P. aeruginosa, MDR 1780 2 (2.5) 0 (0.0) 17 (11.2) 23 (10.7) 39 (10.2) 37 (11.0) 33 (12.5) 9 (14.8) 21 (8.1) 181 (10.2)
ESBL, extended-spectrum β-lactamase; BL-Pos, β-lactamase-positive; MDR, multidrug-resistant; MRSA, methicillin-resistant S. aureus; PRSP, penicillin-resistant S.
pneumoniae; VRE, vancomycin-resistant Enterococcus.
Results do not exactly match those presented by Nørskov-Lauritsen et al. [7] due to subsequent addition and deletion of isolates from the T.E.S.T. database.
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Imipenem (n = 260) and amikacin were the most active
agents against P. aeruginosa with 87.7% and 87.1%
susceptibility, respectively (Table 1). A total of 10.2% of
P. aeruginosa isolates were MDR, ranging from 0.0% in
2005 to 14.8% in 2011 (Table 3).
Discussion
This report updates data previously presented by Rodloff
et al. [6] for France (as well as Germany, Italy, Spain and
the U.K.) between 2004 and 2006 and Nørskov-Lauritsen
et al. [7] for data collected between 2004 and 2007. The
data described in their reports are included in the dataset
described in this manuscript. Susceptibility results are dif-
ficult to compare between these two earlier reports and
the current study as CLSI interpretive breakpoints were
used in Rodloff et al. [6] and Nørskov-Lauritsen et al. [7]
while EUCAST breakpoints have been used in the current
manuscript. No vancomycin-resistant enterococci were re-
ported in either earlier study in France; however, small
percentages of vancomycin-resistant E. faecalis (0.7%) and
E. faecium (5.4%) were collected in the current study. As
the data show, the majority of vancomycin-resistant en-
terococci were collected during or after 2008 (three iso-
lates were collected in 2006 and 2007 but were not
reported by Rodloff et al. [6] and Nørskov-Lauritsen et al.
[7] as they were entered into the database after the data
cut-offs for these publications). Rates of MRSA were com-
parable between the three reports (28.3% in the current
study, 28.3% in Rodloff et al. [6], and 31.5% in Nørskov-
Lauritsen et al. [7]); however, the rate of penicillin-
resistant S. pneumoniae was lower in the current study
when compared with Nørskov-Lauritsen et al. [7] (3.2%
and 16.8%, respectively). No S. pneumoniae data was pre-
sented by Rodloff et al. [6]. This difference is likely due inpart to the use of CLSI breakpoints by Nørskov-Lauritsen
et al. (resistance breakpoint ≥2 mg/L, compared to ≥4
mg/L used by EUCAST); the removal of 236 S. pneumo-
niae isolates from the T.E.S.T. database whose MICs could
not be verified (i.e., isolates which could not be revived for
retesting or which died on transport from the contributing
centre to IHMA) may have also influenced this PRSP
difference.
ESBL production among E. coli and K. pneumoniae was
higher in the current study; 12.0% and 18.0% compared
with 4.9% and 9.5% and 5.1% and 9.8% in Rodloff et al. [6]
and Nørskov-Lauritsen et al. [7], respectively. As rates of
ESBLs were higher in the later years of this study (2008
onwards) this difference is not unexpected. Rates of
multidrug-resistant A. baumannii and β-lactamase pro-
ducing H. influenzae were similar between the current
report and Nørskov-Lauritsen et al. [7]. (approximately
5% and 22%, respectively), although the definition of MDR
A. baumannii in Nørskov-Lauritsen et al. [7]. also in-
cluded cephalosporins. Data on multidrug-resistant A.
baumannii and H. influenzae were not reported by
Rodloff et al. [6]. As the isolates presented by Rodloff
et al. [6] and Nørskov-Lauritsen et al. [7] are also included
in this report comparisons between these three reported
must be treated with some caution. However, the in-
creases in rates of vancomycin-resistant enterococci,
and ESBL-producing E. coli and K. pneumoniae are
cause for concern and warrant further monitoring.
One factor that could influence the difference in resist-
ance rates between the reports is the presence of centre
specific outbreaks. Outbreaks of resistant pathogens have
been described in several medical centres in France in re-
cent years, caused by carbapenemase-producing [11] or
metallo-β-lactamase-producing K. pneumoniae [12], MDR
A. baumannii [13], glycopeptide-intermediate S. aureus
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outbreaks were controlled with infection control mea-
sures, including strict enforcement of hygiene precautions,
limiting transfer of patients to other wards, isolating
infected patients with dedicated staff and the closure of
infected wards. These outbreaks of highly resistant patho-
gens reinforce the clinical importance of antimicrobial
agents such as tigecycline, daptomycin, linezolid, and
vancomycin, which often retain excellent in vitro activity
against even highly resistant pathogens [16,17].
As a result of a resistance control programme started
in 2003 in 38 French teaching hospitals, vancomycin-
resistant enterococci and carbapenemase-producing
Enterobacteriaceae cases were controlled while MRSA
incidence declined by two thirds; however, a dramatic
increase in the percentage of ESBL-positive Enterobacteri-
aceae was noted [4]. Similarly, a long-term study involving
933 health care facilities carried out by the French national
healthcare-associated infection early-warning, investiga-
tion and surveillance network (RAISIN) led to a 43%
decrease in MRSA while ESBL-positive Enterobacteriaceae
increased by 182% [18]. The epidemiology of ESBL-
producing pathogens can be very complex [19], and
ESBL-positive Enterobacteriaceae are increasing in preva-
lence so rapidly that they may soon become the most
widespread MDR pathogens in French hospitals [20].
ESBL levels among E. coli and K. pneumoniae increased
markedly over the course of the T.E.S.T. study; however,
MRSA levels in the current study decreased between 2004
(34.3%) and 2009 (20.0%) but increased from 2011 (23.4%)
to 2012 (34.7%). This increase in MRSA levels was unex-
pected and may have been due to regional factors such as
localised outbreak(s) of resistant isolates.
In a review of data collected by the Pneumococcus Sur-
veillance Network (PSN) in France in 2007, Kempf et al.
[21] reported a PRSP percentage of 6.6% among S. pneu-
moniae isolates collected from adults and children. This
PRSP occurrence is twice that recorded in the current
manuscript for France between 2004 and 2012, and three
times higher than the value reported in T.E.S.T. for 2007
alone. This difference is due in part to Kempf et al. [21]
using a resistance breakpoint of >1 mg/L for penicillin,
compared with ≥4 mg/L used in this T.E.S.T. study.
Sizeable (>20%) regional variations in the prevalence of
penicillin-non-susceptible S. pneumoniae and a high
number of isolates collected from children (27.9%) were
also reported by Kempf et al. [21].
Tigecycline and linezolid demonstrated good activity
against the Gram-positive isolates in this study. In the case
of enterococci the activity of tigecycline and linezolid has
also been demonstrated by others [15,22,23]. Bourdon
et al. [15] performed susceptibility testing on 602 E.
faecium and 30 E. faecalis isolates, all VRE, collected
from 112 French hospitals between 2006 and 2008 andobserved 100% susceptibility to tigecycline and linezolid.
Similarly, Marcadé et al. [22] described seven glycopeptide-
resistant E. faecium isolates from a single hospital in
Paris which possessed both vanA and vanB resistance
genes; all were susceptible to tigecycline and linezolid,
as well as daptomycin. Bérenger et al. [23] examined 60
glycopeptide-resistant, epidemiologically unrelated clin-
ical isolates of E. faecium collected in France between
2006 and 2008; all were susceptible to linezolid while
59 were tigecycline-susceptible (the remaining isolate
had intermediate susceptibility for tigecycline).
In the current T.E.S.T. report, the levels of β-lactamase
positive isolates of H. influenzae fluctuated year-on-year
(between 18.1% and 27.7%) between 2004 and 2012, with
no discernible pattern over time. A statistically significant
decrease in the occurrence of β-lactamase-positive,
ampicillin-resistant isolates among non-typeable H. influ-
enzae was reported in France between 2001 and 2008
[24], with the rate decreasing from 35.6% in 2001–02 to
13.5% in 2007–08; however, this study only included
isolates collected from patients ≤5 years in age.
Conclusions
Programmes aimed at controlling and/or reducing the
prevalence of drug-resistant pathogens in France have
been successful against some important pathogens, such
as MRSA and VRE, but other resistant pathogens con-
tinue to increase in prevalence across the country, most
notably ESBL-positive Enterobacteriaceae. These trends
highlight the importance of surveillance studies such as
T.E.S.T., which monitor pathogen resistance rates against
key antimicrobial agents both nationally and globally.
Tigecycline possesses good in vitro activity against many
resistant pathogens, including ESBL producers, and thus
could be a useful tool in the treatment of resistant infec-
tions in France in the future.
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